Aurinia Pharmaceuticals Inc.

AUPH· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$14.57-2.08%

2026-08-03

Financials

Valuation Metrics

Aurinia Pharmaceuticals Inc.'s Market Cap is $1.87B. At end of 2025 it was $2.14B. Ranked #2098 of 3,112 in US market (top 67%), #811 of 1,445 on NASDAQ (top 56%), #143 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$1.87B	US#2,098/3,112 Sec#143/269
Revenue	$298M	US#2,560/3,112 Sec#98/269
Net Income	$298M	US#1,066/3,112 Sec#38/269
Total Assets	$724M	US#2,589/3,112 Sec#122/269
Net Assets	$568M	US#2,167/3,112 Sec#101/269
Value
P/E	6.28x	US#77/3,112 Sec#7/269
P/B	3.30x	US#1,787/3,112 Sec#100/269
PEG	0.13x	US#234/3,112 Sec#10/269
P/S	6.28x	US#2,418/3,112 Sec#97/269
EV/EBITDA	11.75x	US#1,021/3,112 Sec#33/269
FCF Yield	8.84%	US#612/3,112 Sec#20/269
Profitability
ROE	52.54%	US#109/3,112 Sec#13/269
ROA	41.19%	US#13/3,112 Sec#4/269
Op. Margin	41.73%	US#210/3,112 Sec#11/269
Revenue Growth	24.40%	US#618/3,112 Sec#73/269
Earnings Growth	47.17%	US#589/3,112 Sec#28/269
Financial Health
Debt Ratio	27.55%	US#297/3,112 Sec#97/269
Total Debt	$69M	US#2,478/3,112 Sec#140/269
FCF	$166M	US#1,445/3,112 Sec#50/269
Cash	$41M	US#2,662/3,112 Sec#236/269
Current Ratio	5.55x	US#431/3,112 Sec#134/269
Net Debt/EBITDA	0.17x	US#703/3,112 Sec#40/269
Performance
1Y Return	38.89%	US#1,279/3,112 Sec#150/269
1M Return	-6.66%	US#2,388/3,112 Sec#138/269
From 52W High	-24.31%	US#1,912/3,112 Sec#133/269
1Y MDD	-21.75%	US#818/3,112 Sec#39/269
Trading
Volume	1,367,549 shares	US#1,200/3,112 Sec#115/269
Trading Value	$20M	US#1,958/3,112 Sec#147/269
Per Share
EPS	$2.14	US#1,225/3,112 Sec#40/269
BPS	$4.33	US#2,287/3,112 Sec#143/269